FGF2 and hepatocellular carcinoma: In this current study, a comparative analysis of the efficacy and post-therapeutic changes in the serum levels of bFGF and VEGF in 53 patients with primary HCC treated with lenvatinib combined with sequential TACE and 51 patients treated with TACE alone was retrospectively conducted.